Latest news
Biocon announces commercial launch of Yesafili in USA - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 18:16:32 GMTBiocon Launches Yesafili in US, Eyes H2 Growth With Existing Contracts - scanx.tradescanx.trade · Wed, 05 Aug 2026 02:59:22 GMTBiocon Launches Yesafili™ Biosimilar for Eye Diseases in the US - Machine MakerMachine Maker · Tue, 04 Aug 2026 12:14:26 GMTBiocon debuts aflibercept biosimilar in US - ET PharmaET Pharma · Tue, 04 Aug 2026 09:54:14 GMTBiocon launches interchangeable biosimilar Yesafili for retinal diseases in US market - Indian Pharma PostIndian Pharma Post · Tue, 04 Aug 2026 06:21:06 GMTBiocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg - Business WireBusiness Wire · Mon, 03 Aug 2026 11:05:00 GMTBiocon moves up on launching Yesafili in United States - Investment GuruInvestment Guru · Mon, 03 Aug 2026 08:05:16 GMTBiocon Launches Yesafili in US, Stock Touches Day High of Rs 429 - EquitypanditEquitypandit · Mon, 03 Aug 2026 05:37:13 GMT